Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005854 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005854: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00005854 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005854, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG methotrexate
- PROCEDURE allogeneic bone marrow transplantation
- DRUG cyclosporine
- PROCEDURE in vitro-treated bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2000-10 |
| Phase | Phase 2 |
What the finished NCT00005854 record still lists
NCT00005854 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005854 about?
NCT00005854 is a clinical study titled "Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.
What is the current status of trial NCT00005854?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2000-10.
What interventions are being tested in trial NCT00005854?
The interventions under investigation include: cyclophosphamide (DRUG), methotrexate (DRUG), allogeneic bone marrow transplantation (PROCEDURE), cyclosporine (DRUG), in vitro-treated bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00005854?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia